GW Taps Julie E. Bauman, MD, MPH, Renowned Cancer Clinician and Researcher, to Serve as Director of the GW Cancer Center
January 26, 2022
Announcement (Jan. 26, 2022) — The George Washington University (GW) is pleased to announce that Julie E. Bauman, MD, MPH, will join its academic medical enterprise to serve as the director of the GW Cancer Center. In this role, Bauman will build on the momentum of the last five years to enhance…
September 9, 2020
WASHINGTON (Sept. 9, 2020) - Spironolactone is not associated with increased risk of female breast cancer recurrence, according to research from the George Washington University (GW) Department of Dermatology.
August 5, 2020
Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the top-tier journal Cancer Research by investigators at the George Washington University (GW) Cancer Center.
July 15, 2020
The National Institutes of Health has awarded $3.6 million to Rebecca Lynch, PhD, assistant professor of microbiology, immunology, and tropical medicine at the George Washington University (GW) School of Medicine and Health Sciences and member of the GW Cancer Center, to investigate HIV-1…
July 9, 2020
Recognized cancer prevention and control expert Elmer E. Huerta, MD, MPH, will serve as the director of the Cancer Preventorium at the George Washington University (GW) Cancer Center and as professor of medicine at the GW School of Medicine and Health Sciences.
May 5, 2020
Enrollment in a supportive oncodermatology program is associated with a significantly improved quality of life score, according to a recent survey from the George Washington University (GW) Cancer Center. The results of the survey were published in the Journal of Drugs in Dermatology.
April 27, 2020
GW dermatology experts are available to speak for media stories during Skin Cancer Awareness Month.
March 23, 2020
Researchers at the GW Cancer Center published a new knowledgebase and web portal, OncoMX, which will improve the exploration and research of cancer biomarkers in the context of related evidence.
GW Cancer Center Expands Clinical Trial Offerings for Patients with High Risk Cutaneous Squamous Cell Carcinoma
January 14, 2020
WASHINGTON (January 22, 2020) - The Cutaneous Oncology Program at the George Washington University (GW) Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma.
GW Cancer Center Researchers Find Potential Therapeutic Target for Prostate Cancers with PTEN Mutation
September 24, 2019
WASHINGTON (Sept. 24, 2019) - PTEN, a tumor suppressor gene mutated in approximately 20% of primary prostate cancers, and in as many as 50% of androgen deprivation-resistant prostate cancers, relies on another gene, ARID4B, to function.